Search

The Widman Lab within the Digital Oncology Program at MSKCC is using machine learning and genomics to engineer the next-generation of ultrasensitive, highly scalable liquid biopsies for early cancer detection, treatment monitoring, and detection of minimal residual disease (MRD) after surgery for early-stage cancer.

… The Widman lab within the Digital Oncology Program at MSKCC is using machine learning and genomics to engineer the next-generation of ultrasensitive, highly scalable liquid biopsies for early cancer detection, treatment monitoring, and detection of minimal residual disease (MRD) after surgery for early-stage

Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

… Soft tissue sarcoma is a heterogeneous disease with more than 50 histological subtypes, which have diverse biological behavior and – in many cases – unique genetics. Many sarcoma subtypes respond poorly to chemotherapy, so there is an urgent need for better treatment options for patients whose disease

Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung and pancreatic cancers.

… The Tammela lab is interested in understanding the remarkable phenotypic heterogeneity of cancer cells within tumors. We approach this question using a combination of sophisticated genetically engineered mouse models, single-cell approaches, tracing and ablation of distinct tumor cell lineages, CRISPR-mediated

The Studer laboratory investigates human stem cells as tools to understand normal and pathological development in the nervous system and to develop cell-based strategies for regenerative medicine.

… Our laboratory aims at exploiting recent advances in stem cell biology to develop radically new therapies for degenerative disease and cancer. The main focus in the lab is on the biology and application of human embryonic stem (ES) and human induced pluripotent (iPS) cells. Pluripotent stem cells can

Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.

… Our research is based on the underlying hypothesis that the ability to inhibit an oncogenic pathway and block cancer growth will vary based on cell lineage and the complement of mutations within the tumor. To design rational therapeutic studies, we must define not only the spectrum of genetic changes

Physician-scientist David R. Jones studies molecular mechanisms governing the development of metastases in lung and esophageal cancers.

… The primary reason people die from cancer is the development of metastatic disease. As a surgeon-scientist who cares for patients with earlier stage lung and esophageal cancer, my laboratory studies why patients with completely resected cancer still develop metastases and die. We focus on a class of

Systems biologist Joao Xavier combines experimental and computational approaches to study diverse problems relevant to cancer: how the microbiome influences cancer and cancer treatment, how cancer cells metastasize, and how metabolic fluxes command the behavior of living cells.

… We combine computation and experiment to investigate how cells interact with each other to produce complex cell group behaviors. Joao Xavier, PhD Member, Computational & Systems Biology Program Professor PhD, Universidade Nova de Lisboa Achievements Director's New Innovator Award, National Institutes

Our group, the Laboratory of Experimental Cancer Immunogenomics, is a multi-disciplinary team of cancer scientists working at the intersection of genomics, molecular genetics, animal modeling, and biostatistical data sciences.

… Our group, the Laboratory of Experimental Cancer Immunogenomics, is a multi-disciplinary team of cancer scientists working at the intersection of  genomics ,  molecular genetics ,  animal modeling, and biostatistical data sciences . We are a mix of experienced researchers, postdoctoral fellows, clinical

Human Oncology and Pathogenesis Program Chair Charles Sawyers develops molecularly targeted cancer therapy.

… Dr. Sawyers is an HHMI Investigator searching for molecularly targeted approaches to treat cancer. He has identified cell signaling components critical to the growth of cancer cells in chronic myeloid leukemia, prostate and other cancers, resulting in the development of multiple FDA-approved inhibitors

Physician-scientist Martin Weiser investigates the mechanisms underlying tumor spread and metastasis and how these mechanisms could be targeted.

… Our research investigates the natural history, molecular biology, and treatment response of cancers of the rectum and colon with the goal of personalizing therapy to reduce treatment toxicity, increase survival, and improve post-treatment quality of life.  We have built and tested clinical calculators